Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**7-Hydroxy–2-Oxo–Chromene–3-Carboxylic Acid Ethyl Ester** is a synthetic small molecule belonging to the class of coumarin derivatives, specifically chromenes. It features a benzopyran ring system with hydroxyl and carboxylic ester functional groups. This compound has been investigated for its potential pharmacological properties, including antimicrobial and anticancer activities, though it is not approved for any clinical use. Mechanistically, some research suggests it may act as an inhibitor of macrophage migration inhibitory factor (MIF), which could be relevant in inflammation or cancer biology[5][10][3]. However, no approved indications or advanced clinical trials are reported for this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 7-hydroxy-2-oxo-chromene-3-carboxylic acid ethyl ester.